VivoSeq
Other

ES-SCLC

0

Pipeline Programs↗

3

Active Trials↗

1

Companies Involved↗

ES-SCLC is an early-stage landscape with 0 programs across 1 company. The most active players are Ariceum Therapeutics GmbH.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

0/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Ariceum Therapeutics GmbH

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

4

clinical trials

Recruiting2 · 50%
Not yet recruiting1 · 25%
Terminated1 · 25%

Clinical Trials

Trial Activity

Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC
Recruiting·RRayzeBio, Inc.·Phase 1·NCT05595460·49 enrolled
Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC
Not yet recruiting·GGuangzhou Institute of Respiratory Disease·Phase 2·NCT06497530·30 enrolled
Iadademstat + SBRT With Atezo in ES-SCLC
Recruiting·YYale University·Phase 1·NCT07113691·15 enrolled
Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )
Terminated·AAriceum Therapeutics GmbH·Phase 1/2·NCT06939036·2 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)